Denali Therapeutics Inc (NASDAQ: DNLI) stock jumped 3.47% on Friday to $18.76 against a previous-day closing price of $18.13. With 1.06 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.85 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $19.08 whereas the lowest price it dropped to was $18.07. The 52-week range on DNLI shows that it touched its highest point at $33.31 and its lowest point at $15.45 during that stretch. It currently has a 1-year price target of $51.38. Beta for the stock currently stands at 1.12.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of DNLI was up-trending over the past week, with a rise of 15.66%, but this was down by -0.64% over a month. Three-month performance dropped to -19.38% while six-month performance fell -40.60%. The stock lost -38.75% in the past year, while it has lost -32.54% so far this year. A look at the trailing 12-month EPS for DNLI yields -0.97 with Next year EPS estimates of -2.79. For the next quarter, that number is -0.81. This implies an EPS growth rate of 59.68% for this year and -166.27% for next year.
Float and Shares Shorts:
At present, 135.97 million DNLI shares are outstanding with a float of 113.73 million shares on hand for trading. On Oct 30, 2023, short shares totaled 10.73 million, which was 7.76% higher than short shares on Sep 28, 2023. In addition to Dr. Ryan J. Watts Ph.D. as the firm’s Co-Founder, President, CEO & Director, Dr. Alexander O. Schuth M.D. serves as its Co-Founder, CFO, COO & Secretary.
Institutional Ownership:
Through their ownership of 80.44% of DNLI’s outstanding shares, institutional investors have majority control over the company.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for DNLI since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With DNLI analysts setting a high price target of $105.00 and a low target of $26.00, the average target price over the next 12 months is $51.38. Based on these targets, DNLI could surge 459.7% to reach the target high and rise by 38.59% to reach the target low. Reaching the average price target will result in a growth of 173.88% from current levels.
Summary of Insider Activity:
Insiders traded DNLI stock several times over the past three months with 0 Buys and 7 Sells. In these transactions, 0 shares were bought while 12,916 shares were sold. The number of buy transactions has increased to 25 while that of sell transactions has risen to 50 over the past year. The total number of shares bought during that period was 399,166 while 283,235 shares were sold.
